QOL Medical and Their CEO Settle for $4.7 Million Over Alleged Kickback Scheme Involving Genetic Testing and Drug Claims
QOL Medical, LLC, and its CEO Frederick E. Cooper have agreed to a $4.7 million settlement with the Department of Justice (DOJ). The settlement resolves allegations that the company provided kickbacks to healthcare providers to induce prescriptions of their drug, Sucraid. This drug is FDA-approved for Congenital Sucrase-Isomaltase Deficiency (CSID), a rare genetic condition that hampers the digestion of sugar.
The allegations against QOL Medical highlight a new practice within the pharmaceutical industry sector: offering free diagnostic tests as incentives for prescribing specific medications. According to the DOJ, QOL provided complimentary Carbon-13 (C13) breath testing kits to healthcare providers. These kits were intended for patients exhibiting common gastrointestinal symptoms, ostensibly to diagnose CSID. However, the DOJ claimed that the test was also sensitive to other conditions that could yield similar test results, suggesting that the tests were not as definitive as QOL portrayed.
QOL’s approach to marketing Sucraid was also under scrutiny. The company allegedly paid a laboratory to conduct the tests and share the results, not only with the ordering healthcare providers but also with QOL. This information included the provider’s name and details about the patient’s age, gender, symptoms, and test outcomes—data that was then reportedly used by QOL’s sales team to target their pitches effectively.
The sales tactics employed by QOL were particularly aggressive. The DOJ highlighted instances where sales representatives were instructed to follow up on positive test results with healthcare providers to promote Sucraid prescriptions. This strategy was supported by training materials that inaccurately touted the C13 test’s ability to conclusively diagnose CSID, according to the DOJ a claim not necessarily backed by scientific evidence.
This settlement brings to light several critical issues within pharmaceutical marketing and diagnostic testing practices:
- Accuracy and Misrepresentation: The DOJ criticized the reliability of the C13 test, concerned about potential false positives and the broad interpretation of results to favor QOL’s drug.
- Privacy and Ethical Marketing: The use of detailed patient data to drive targeted sales strategies raises significant ethical and privacy concerns, reflecting a growing scrutiny of how sensitive health information is handled in the industry.
- Corporate Misconduct: The government’s disapproval extends to the misrepresentation of a product’s benefits, especially when driven by a coordinated company effort, as was evidenced in QOL’s case.
The settlement also includes provisions for cooperation with ongoing regulatory requirements, separation of costs related to the settlement from future billing, and several protections and releases for the involved parties, ensuring compliance with federal healthcare program standards.
The QOL Medical case serves as a cautionary tale for the pharmaceutical industry and executive’s, as it is rare for the executives to also have to pay in these types of settlements not to overstate claims or provide tests and utilize those results in targeting.
Additional Resources